The U.S. Food and Drug Administration (FDA) approved Descovy for use in adults and adolescents on April 4, 2020 [1].
What is Descovy used for?
Descovy is a prescription medication used to treat HIV-1 infection in adults and adolescents. It is also used as a pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in certain adults and adolescents at high risk [2].
What are the active ingredients in Descovy?
Descovy is a combination medication containing emtricitabine and tenofovir alafenamide [2].
When does Descovy patent protection expire?
Patent information for Descovy can be complex and may involve multiple patents covering different aspects of the drug, such as formulation and use. DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods, which can provide detailed information on when patent protection is expected to expire for specific drugs like Descovy [3].
Can generic versions of Descovy be made?
The availability of generic versions of Descovy is dependent on the expiration of its patents and any other market exclusivities granted by regulatory authorities. Once these protections expire, other companies may be able to develop and market generic alternatives [3].
What clinical trials led to Descovy's FDA approval?
The FDA's approval of Descovy was based on the results of clinical trials that demonstrated its efficacy and safety for its approved uses. These trials assessed the drug's ability to suppress HIV-1 viral load and prevent HIV-1 acquisition in PrEP settings [1][2].